Stiripentol identifies a therapeutic target to reduce oxaluria.
Letavernier E, Daudon M.
Curr Opin Nephrol Hypertens. 2020 Jul;29(4):394-399. doi: 10.1097/MNH.0000000000000621.
Oxalate homeostasis.
Ermer T, Nazzal L, Tio MC, Waikar S, Aronson PS, Knauf F.
Nat Rev Nephrol. 2023 Feb;19(2):123-138. doi: 10.1038/s41581-022-00643-3. Epub 2022 Nov 3.
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope.
Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O, Cerkauskiene R, Ferraro PM, Groen LA, Gupta A, Knebelmann B, Mandrile G, Moochhala SS, Prytula A, Putnik J, Rumsby G, Soliman NA, Somani B, Bacchetta J.
Nat Rev Nephrol. 2023 Mar;19(3):194-211. doi: 10.1038/s41581-022-00661-1. Epub 2023 Jan 5.
Diagnosis and management of primary hyperoxalurias: best practices.
Michael M, Harvey E, Milliner DS, Frishberg Y, Sas DJ, Calle J, Copelovitch L, Penniston KL, Saland J, Somers MJG, Baum MA.
Pediatr Nephrol. 2024 Nov;39(11):3143-3155. doi: 10.1007/s00467-024-06328-2. Epub 2024 May 16.
Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.
Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M.
Am J Kidney Dis. 2022 May;79(5):717-727. doi: 10.1053/j.ajkd.2021.07.018. Epub 2021 Sep 9.
Primary hyperoxaluria.
Lorenzo V, Torres A, Salido E.
Nefrologia. 2014 May 21;34(3):398-412. doi: 10.3265/Nefrologia.pre2014.Jan.12335. Epub 2014 Apr 30.
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, Tönshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B; PHYOX2 study investigators.
Kidney Int. 2023 Jan;103(1):207-217. doi: 10.1016/j.kint.2022.07.025. Epub 2022 Aug 22.
Pathophysiology and management of enteric hyperoxaluria.
Desenclos J, Forté V, Clément C, Daudon M, Letavernier E.
Clin Res Hepatol Gastroenterol. 2024 May;48(5):102322. doi: 10.1016/j.clinre.2024.102322. Epub 2024 Mar 19.
Future treatments for hyperoxaluria.
Burns Z, Knight J, Fargue S, Holmes R, Assimos D, Wood K.
Curr Opin Urol. 2020 Mar;30(2):171-176. doi: 10.1097/MOU.0000000000000709.
Pathophysiology and management of enteric hyperoxaluria.
Joly PF.
Clin Res Hepatol Gastroenterol. 2024 Jun;48(6):102359. doi: 10.1016/j.clinre.2024.102359. Epub 2024 May 10.
